Literature DB >> 140196

Multiple myeloma: an immunologic profile. I. Peripheral blood studies.

M R MacKenzie, T Paglieroni.   

Abstract

Seventy-four patients with multiple myeloma, 17 untreated and 57 treated, were studied to characterize their peripheral blood lymphocytes. PBL were studied for E, EAC, and EA rosette-forming cells, SIg, and Fc receptor-bearing cells. The responses to HA, Con A, and PWM were assessed as well as their ability to stimulate or to respond in a MLC. Finally, the capacity of mitogen-stimulated lymphocytes to lyse Chang cells, CRBC, and PHA-stimulated lymphoblasts was examined. These results were compared with a group of normals and patients with benign monoclonal gammopathy. In untreated myeloma patients there was a normal percentage of T cells, but an abnormal distribution of B cells as judged by a decrease in SIg-bearing cells, as well as an increase in EAC rosette-forming cells. Subpopulation analysis showed a marked increase in EAC rosette-forming cells without SIg. PHA, Con A, and PWM, and response in MLC were all normal. However, the ability to stimulate in MLC was significantly depressed. Treated myeloma patients had similar findings, except that the response to PWM was significantly depressed. The capacity of PWM-stimulated cells to lyse target cells was depressed in both groups. The results indicate that, in the peripheral blood of myeloma patients, there are populations of lymphocytes characterized by the presence of the EAC receptor without SIg, which are deficient in the capacity to stimulate an MLC response and the ability to be cytotoxic when stimulated by PWM. The results form a baseline for the study of abnormal lymphoid function in human myeloma.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 140196

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  10 in total

1.  Terminal B cell development as seen in different human myelomas and related disorders.

Authors:  G F Burns; C P Worman; B E Roberts; C G Raper; C R Barker; J C Cawley
Journal:  Clin Exp Immunol       Date:  1979-02       Impact factor: 4.330

Review 2.  Mechanisms in secondary hypogammaglobulinaemia.

Authors:  P G Riches; J R Hobbs
Journal:  J Clin Pathol Suppl (R Coll Pathol)       Date:  1979

3.  Effect of treatment with thymustimulin (Tp-1) on T and B cells in lymphoproliferative disorders.

Authors:  P Pontiggia; C Ogier; G D Follini
Journal:  Blut       Date:  1983-09

4.  PWM-induced generation of immunoglobulin-secreting cells in patients with multiple myeloma.

Authors:  G Sieber; B Enders; H Rühl
Journal:  Klin Wochenschr       Date:  1981-10-01

5.  The mode of action of splenic suppressor cells in murine plasmacytoma.

Authors:  Y Chen; P Heller
Journal:  Clin Exp Immunol       Date:  1981-09       Impact factor: 4.330

6.  Sex hormones and immune dysregulation in multiple myeloma.

Authors:  H Everaus; J Lehtmaa
Journal:  Cancer Immunol Immunother       Date:  1993       Impact factor: 6.968

7.  Use of immunologic markers in obscure hematologic disease.

Authors:  C H Miller; S Mann; J Hamersley; F J Glassy; L F O'Grady
Journal:  West J Med       Date:  1983-10

8.  Delay and not deficiency in cap formation of peripheral blood B cells in patients with multiple myeloma.

Authors:  X G Zhang; B Klein; C Duperray; J Brochier; R Bataille
Journal:  J Clin Immunol       Date:  1988-07       Impact factor: 8.317

9.  Coccidioidomycosis: early immunologic findings.

Authors:  C H Miller; M R MacKenzie; T Paglieroni; E Goldstein
Journal:  West J Med       Date:  1983-01

10.  The defect in peripheral blood B-cell activation in patients with multiple myeloma is not due to a deficiency in the production of B-cell growth and differentiation factors.

Authors:  T Commes; B Klein; M Jourdan; G Clofent; F Houssiau; J Grenier; R Bataille
Journal:  J Clin Immunol       Date:  1989-01       Impact factor: 8.317

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.